← 홈

Antibody · 혈액암 (AML/ALL)

286개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 286개
AntibodyHotRocheatApproved

Bevacizumab (Bevacizumab)

Colorectal Neoplasms · Recurrent Platinum-Sensitive Fallopian T

#RecurrentPlatinum-SensitiveFallo#Antibody#Approved#인기#항체+5
효능 ORR 100%임상시험 1131상태 RECRUITING
AntibodyHotEli LillyreleaseApproved

Cetuximab (Cetuximab)

Locally Recurrent Skin Squamous Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Approved#인기#항체+5
효능 ORR 100%임상시험 757상태 RECRUITING
AntibodyHotRochederuxtecan (Dato-DXd, Datro…Approved

trastuzumab (Herceptin)

Non Small Cell Lung Cancer; Colorectal Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#Antibody#Approved#인기#항체+5
효능 ORR 91.8%임상시험 676상태 RECRUITING
AntibodyHotRochePhase 3

atezolizumab (Tecentriq)

Advanced Solid Tumor · Thoracic Neoplasms, Lung Diseases, Small

#ThoracicNeoplasmsLungDiseasesSma#Antibody#Phase3#인기#항체+5
효능 ORR 95%임상시험 648상태 RECRUITING
AntibodyBHotMerckVedotin ± Pe…Phase 3

Pembrolizumab (Immunotherapy, Immunotherapy (Pembrolizumab))

Melanoma (Skin Cancer); Melanoma Stage IIIB-IV · Locally Advanced Esophageal Squamous Cel

#LocallyAdvancedEsophagealSquamou#Antibody#Phase3#인기#항체+5
효능 ORR 41.6%임상시험 155상태 RECRUITING
AntibodyBHotJanssenPhase 2

Subcutaneously (Daratumumab, Daratumumab (Subcutaneously))

Primary Plasma Cell Leukemia · Primary Plasma Cell Leukemia

#PrimaryPlasmaCellLeukemia#Antibody#Phase2#인기#항체+3
효능 ORR 91.8%임상시험 147상태 RECRUITING
AntibodyAHotRocheApproved

Tocilizumab (Tocilizumab)

Multiple Myeloma (MM); Multiple Myeloma Refractory · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Approved#인기#항체+5
효능 ORR 95%임상시험 115상태 RECRUITING
AntibodyBHotMerck KGaAvedotin (EV) was the most c…Phase 3

Avelumab (Avelumab)

Non Small Cell Lung Cancer; Colorectal Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#Antibody#Phase3#인기#항체+5
효능 ORR 74%임상시험 105상태 ACTIVE
AntibodyCHotXin-Hua XuPhase 2

AK104 (Cadonilimab, Cadonilimab (AK104))

Non-small Cell Lung Cancer · Leptomeningeal Metastasis

#LeptomeningealMetastasis#Antibody#Phase2#인기#항체+5
임상시험 101상태 RECRUITING
AntibodyCBeiGeneVedotin, Tislelizumab, and …Phase 2

Tislelizumab (Tislelizumab)

Locally Recurrent Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#인기#항체+5
효능 ORR 37.1%임상시험 96상태 RECRUITING
AntibodyARochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody)

Carcinoma, Non-Squamous Non-Small Cell Lung · PD-L1

#PD-L1#Antibody#Phase3#인기#항체+5
효능 ORR 76.7%임상시험 88상태 ACTIVE
AntibodyCEli Lilly and CompanyDeruxtecan]Phase 3

Ramucirumab (Ramucirumab)

Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase3#인기#항체+5
효능 ORR 40%임상시험 86상태 RECRUITING
AntibodyARocheGovitecanPhase 3

carboplatin-etoposide (Atezolizumab + chemotherapy, Atezolizumab + chemotherapy (carboplatin-etoposide))

Extensive Stage Small Cell Lung Cancer · Extensive Stage Small Cell Lung Cancer

#ExtensiveStageSmallCellLungCance#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 83상태 RECRUITING
AntibodyCAmgenPhase 3

Blinatumomab (Blinatumomab)

B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#Antibody#Phase3#인기#항체+5
효능 ORR 11.1%임상시험 83상태 RECRUITING
AntibodyCMiltenyi Biomedicine GmbHPhase 3

Alemtuzumab (Alemtuzumab)

Leukemia; Lymphoma · Fanconi Anemia

#FanconiAnemia#Antibody#Phase3#인기#항체+5
효능 ORR 33%임상시험 71상태 DISCONTINUED
AntibodyRocheApproved

Omalizumab (Omalizumab)

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP); Chronic Rhinosinusitis (CRS) · Persistent Allergic Asthma

#PersistentAllergicAsthma#Antibody#Approved#인기#항체+5
임상시험 67상태 ACTIVE
AntibodyHoffmann-La Rochevedotin plus bendamustine a…Phase 3

Glofitamab (Glofitamab)

Diffuse Large B Cell Lymphoma (DLBCL); High Grade B Cell Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase3#인기#항체+5
임상시험 66상태 RECRUITING
AntibodyAstraZenecavedotin combined with pembr…Phase 3

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase3#인기#항체+5
효능 ORR 36.3%임상시험 65상태 ACTIVE
AntibodyNovartisPhase 3

Ofatumumab (Ofatumumab)

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma · Leukemia

#Leukemia#Antibody#Phase3#인기#항체+5
효능 ORR 78.4%임상시험 65상태 RECRUITING
AntibodyMerckvedotin after avelumabPhase 1

pembrolizumab (Keytruda, Pembrolizumab (+) Berahyaluronidase alfa)

Advanced or Metastatic Solid Tumors · Metastatic Non-small Cell Lung Cancer

#MetastaticNon-smallCellLungCance#Antibody#Phase1#인기#항체+5
효능 ORR 65.1%임상시험 63상태 ACTIVE

1 / 15 페이지

← 이전다음 →